Brokerages Anticipate Forty Seven Inc (FTSV) Will Announce Earnings of -$0.56 Per Share

Share on StockTwits

Wall Street analysts expect Forty Seven Inc (NASDAQ:FTSV) to post earnings per share (EPS) of ($0.56) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Forty Seven’s earnings. The company is scheduled to announce its next quarterly earnings results on Monday, November 12th.

According to Zacks, analysts expect that Forty Seven will report full-year earnings of ($2.96) per share for the current fiscal year, with EPS estimates ranging from ($3.51) to ($2.41). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.73) per share, with EPS estimates ranging from ($3.05) to ($2.41). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Forty Seven.

Forty Seven (NASDAQ:FTSV) last released its earnings results on Monday, August 13th. The company reported ($2.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($1.84).

FTSV has been the topic of several analyst reports. Zacks Investment Research downgraded Forty Seven from a “hold” rating to a “sell” rating in a report on Monday, September 24th. Morgan Stanley initiated coverage on Forty Seven in a report on Monday, July 23rd. They issued an “overweight” rating and a $25.00 target price on the stock. Canaccord Genuity assumed coverage on Forty Seven in a report on Monday, July 23rd. They issued a “buy” rating and a $22.00 target price on the stock. Credit Suisse Group assumed coverage on Forty Seven in a report on Monday, July 23rd. They set an “outperform” rating and a $24.00 price target on the stock. Finally, Oppenheimer assumed coverage on Forty Seven in a report on Monday, July 23rd. They set an “outperform” rating and a $35.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $26.75.

In other Forty Seven news, major shareholder Ravi Mhatre purchased 166,858 shares of the stock in a transaction dated Thursday, August 23rd. The shares were purchased at an average cost of $15.08 per share, with a total value of $2,516,218.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Christopher J. Schaepe purchased 66,542 shares of the stock in a transaction dated Thursday, August 16th. The shares were acquired at an average cost of $15.03 per share, for a total transaction of $1,000,126.26. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 300,900 shares of company stock worth $4,540,995.

Several large investors have recently made changes to their positions in FTSV. Point72 Hong Kong Ltd bought a new position in Forty Seven in the second quarter valued at about $120,000. Waddell & Reed Financial Inc. bought a new position in Forty Seven in the second quarter valued at about $160,000. Janus Henderson Group PLC bought a new position in Forty Seven in the second quarter valued at about $160,000. DAFNA Capital Management LLC bought a new position in Forty Seven in the second quarter valued at about $160,000. Finally, TD Asset Management Inc. bought a new position in Forty Seven in the second quarter valued at about $215,000. 41.05% of the stock is currently owned by hedge funds and other institutional investors.

Forty Seven stock opened at $14.58 on Tuesday. Forty Seven has a 12 month low of $12.16 and a 12 month high of $16.86.

Forty Seven Company Profile

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors.

Recommended Story: Market Capitalization

Get a free copy of the Zacks research report on Forty Seven (FTSV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Forty Seven (NASDAQ:FTSV)

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.